Collegium Pharmaceutical, Inc. (COLL)
Market Cap | 1.05B |
Revenue (ttm) | 566.92M |
Net Income (ttm) | 93.29M |
Shares Out | 32.72M |
EPS (ttm) | 2.41 |
PE Ratio | 13.29 |
Forward PE | 4.84 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 272,082 |
Open | 32.53 |
Previous Close | 32.62 |
Day's Range | 32.03 - 32.86 |
52-Week Range | 20.83 - 40.95 |
Beta | 0.96 |
Analysts | Buy |
Price Target | 40.00 (+24.84%) |
Earnings Date | Aug 1, 2024 |
About COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a bucc... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for COLL stock is "Buy." The 12-month stock price forecast is $40.0, which is an increase of 24.84% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/l/w/conf17-2451343.jpg)
Collegium to Participate in Jefferies Global Healthcare Conference
STOUGHTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people liv...
![](https://cdn.snapi.dev/images/v1/m/a/press14-2426730.jpg)
Collegium Announces $35 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people liv...
![](https://cdn.snapi.dev/images/v1/h/f/press6-2422488.jpg)
Collegium Reports First Quarter 2024 Financial Results
– Generated Q1'24 Net Revenue of $144.9 Million – – Delivered Q1'24 Record Belbuca ® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1'24 GAAP Net Income of $27.7 Mi...
![](https://cdn.snapi.dev/images/v1/1/h/conf12-2390847.jpg)
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people l...
![](https://cdn.snapi.dev/images/v1/4/z/press6-2366984.jpg)
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the l...
![](https://cdn.snapi.dev/images/v1/s/j/press2-2289708.jpg)
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record...
![](https://cdn.snapi.dev/images/v1/w/s/conf4-2266785.jpg)
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...
![](https://cdn.snapi.dev/images/v1/1/c/press6-2171975.jpg)
Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent
STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appea...
![](https://cdn.snapi.dev/images/v1/r/r/conf2-2146614.jpg)
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...
![](https://cdn.snapi.dev/images/v1/r/c/press12-2145112.jpg)
Collegium Reports Third Quarter 2023 Financial Results
– Q3'23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3'23 GAAP Net Income of $20.6 Million vs. Q3'22 GAAP Net Income of $0.5 Million – – Record Q3'23 Adjusted EBITDA of $89.4 Million, Up 1...
![](https://cdn.snapi.dev/images/v1/k/a/conf13-2117048.jpg)
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
STOUGHTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...
![](https://cdn.snapi.dev/images/v1/g/h/press11-2039279.jpg)
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...
![](https://cdn.snapi.dev/images/v1/p/p/press7-2035729.jpg)
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...
![](https://cdn.snapi.dev/images/v1/x/0/press18-2009474.jpg)
Collegium Announces $50 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...
![](https://cdn.snapi.dev/images/v1/d/f/press1-2005595.jpg)
Collegium Reports Record 1H'23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
– Q2'23 Net Revenue of $135.5 Million, Up 10% Year-over-Year – – Q2'23 GAAP Net Income of $13.0 Million – – Q2'23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year – – Board of Directors has Aut...
![](https://cdn.snapi.dev/images/v1/8/h/conf4-1979943.jpg)
Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023
STOUGHTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...
![](https://cdn.snapi.dev/images/v1/f/e/press9-1916227.jpg)
Collegium to Participate in Jefferies Healthcare Conference
STOUGHTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...
![](https://cdn.snapi.dev/images/v1/y/w/press13-1872730.jpg)
Collegium Reports First Quarter 2023 Financial Results
– Generated Record Net Revenue of $144.8 Million – – Delivered Record Belbuca ® and Xtampza ® ER Net Revenue – – Ended Q1'23 with Cash Balance of $269.5 Million – – Reaffirmed Full Year 2023 Guidance ...
![](https://cdn.snapi.dev/images/v1/t/j/conf7-1845518.jpg)
Collegium to Report First Quarter 2023 Financial Results on May 4, 2023
STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people l...
![](https://cdn.snapi.dev/images/v1/0/e/press19-1832101.jpg)
Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people l...
![](https://cdn.snapi.dev/images/v1/x/g/press15-1768632.jpg)
Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results
– Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million –
![](https://cdn.snapi.dev/images/v1/4/d/press3-1743586.jpg)
Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% conve...
![](https://cdn.snapi.dev/images/v1/h/g/press13-1740847.jpg)
Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate...
![](https://cdn.snapi.dev/images/v1/l/b/press9-1740841.jpg)
Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
-Results at or above high-end of 2022 earnings guidance-
![](https://cdn.snapi.dev/images/v1/r/8/press11-1694530.jpg)
Collegium Provides 2023 Financial Guidance
– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million –